{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:08:07Z","timestamp":1790388487561,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T00:00:00Z","timestamp":1372896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s11060-013-1201-8","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T21:28:58Z","timestamp":1372886938000},"page":"9-17","source":"Crossref","is-referenced-by-count":39,"title":["Altered galectin-1 serum levels in patients diagnosed with high-grade glioma"],"prefix":"10.1007","volume":"115","author":[{"given":"Tina","family":"Verschuere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Van Woensel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Fieuws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lefranc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan W.","family":"Van Gool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"De Vleeschouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,4]]},"reference":[{"issue":"2","key":"1201_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97\u2013109. doi: 10.1007\/s00401-007-0243-4","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1201_CR2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459\u2013466. doi: 10.1016\/S1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"issue":"8","key":"1201_CR3","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2003.05.063","volume":"21","author":"A Giese","year":"2003","unstructured":"Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21(8):1624\u20131636. doi: 10.1200\/JCO.2003.05.063","journal-title":"J Clin Oncol"},{"issue":"1","key":"1201_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1750-3639.2009.00270.x","volume":"20","author":"M Mercier Le","year":"2010","unstructured":"Le Mercier M, Fortin S, Mathieu V, Kiss R, Lefranc F (2010) Galectins and gliomas. Brain Pathol 20(1):17\u201327. doi: 10.1111\/j.1750-3639.2009.00270.x","journal-title":"Brain Pathol"},{"issue":"11","key":"1201_CR5","doi-asserted-by":"crossref","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","volume":"16","author":"I Camby","year":"2006","unstructured":"Camby I, Le Mercier M, Lefranc F, Kiss R (2006) Galectin-1: a small protein with major functions. Glycobiology 16(11):137R\u2013157R. doi: 10.1093\/glycob\/cwl025","journal-title":"Glycobiology"},{"issue":"1","key":"1201_CR6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1750-3639.2001.tb00377.x","volume":"11","author":"I Camby","year":"2001","unstructured":"Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R (2001) Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11(1):12\u201326","journal-title":"Brain Pathol"},{"issue":"7","key":"1201_CR7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnen\/61.7.585","volume":"61","author":"I Camby","year":"2002","unstructured":"Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ, Kiss R (2002) Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61(7):585\u2013596","journal-title":"J Neuropathol Exp Neurol"},{"key":"1201_CR8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-4598-11-32","volume":"11","author":"LG Toussaint 3rd","year":"2012","unstructured":"Toussaint LG 3rd, Nilson AE, Goble JM, Ballman KV, James CD, Lefranc F, Kiss R, Uhm JH (2012) Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Mol Cancer 11:32. doi: 10.1186\/1476-4598-11-32","journal-title":"Mol Cancer"},{"issue":"2","key":"1201_CR9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.taap.2008.01.009","volume":"229","author":"M Mercier Le","year":"2008","unstructured":"Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V (2008) Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229(2):172\u2013183. doi: 10.1016\/j.taap.2008.01.009","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"1201_CR10","first-page":"483","volume":"18","author":"HM Strik","year":"2007","unstructured":"Strik HM, Schmidt K, Lingor P, Tonges L, Kugler W, Nitsche M, Rabinovich GA, Bahr M (2007) Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 18(2):483\u2013488","journal-title":"Oncol Rep"},{"issue":"43","key":"1201_CR11","doi-asserted-by":"crossref","first-page":"15975","DOI":"10.1073\/pnas.0603883103","volume":"103","author":"VL Thijssen","year":"2006","unstructured":"Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103(43):15975\u201315980. doi: 10.1073\/pnas.0603883103","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1201_CR12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/NEN.0b013e318170f892","volume":"67","author":"M Mercier Le","year":"2008","unstructured":"Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R, Lefranc F (2008) Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67(5):456\u2013469. doi: 10.1097\/NEN.0b013e318170f892","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"1201_CR13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1535-6108(04)00024-8","volume":"5","author":"N Rubinstein","year":"2004","unstructured":"Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5(3):241\u2013251","journal-title":"Cancer Cell"},{"issue":"1","key":"1201_CR14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.oraloncology.2006.12.014","volume":"44","author":"S Saussez","year":"2008","unstructured":"Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C, Kiss R (2008) The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and\/or responses to therapy. Oral Oncol 44(1):86\u201393. doi: 10.1016\/j.oraloncology.2006.12.014","journal-title":"Oral Oncol"},{"issue":"3","key":"1201_CR15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.1002940","volume":"186","author":"PL Kuo","year":"2011","unstructured":"Kuo PL, Hung JY, Huang SK, Chou SH, Cheng DE, Jong YJ, Hung CH, Yang CJ, Tsai YM, Hsu YL, Huang MS (2011) Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3\/IL-10 signaling pathway. J Immunol 186(3):1521\u20131530. doi: 10.4049\/jimmunol.1002940","journal-title":"J Immunol"},{"issue":"15","key":"1201_CR16","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood-2011-12-396457","volume":"119","author":"F Cedeno-Laurent","year":"2012","unstructured":"Cedeno-Laurent F, Watanabe R, Teague JE, Kupper TS, Clark RA, Dimitroff CJ (2012) Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119(15):3534\u20133538. doi: 10.1182\/blood-2011-12-396457","journal-title":"Blood"},{"key":"1201_CR17","author":"J Ouyang","year":"2013","unstructured":"Ouyang J, Plutschow A, Pogge von Strandmann E, Reiners KS, Ponader S, Rabinovich GA, Neuberg D, Engert A, Shipp MA (2013) Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood. doi: 10.1182\/blood-2012-12-474569","journal-title":"Blood"},{"issue":"7","key":"1201_CR18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/thy.2007.0361","volume":"18","author":"S Saussez","year":"2008","unstructured":"Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ, Laurent G (2008) Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18(7):705\u2013712. doi: 10.1089\/thy.2007.0361","journal-title":"Thyroid"},{"issue":"22","key":"1201_CR19","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-11-1462","volume":"17","author":"H Barrow","year":"2011","unstructured":"Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, Chen C, Rhodes JM, Yu LG (2011) Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17(22):7035\u20137046. doi: 10.1158\/1078-0432.CCR-11-1462","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1201_CR20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1011874800612","volume":"53","author":"HM Strik","year":"2001","unstructured":"Strik HM, Deininger MH, Frank B, Schluesener HJ, Meyermann R (2001) Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol 53(1):13\u201320","journal-title":"J Neurooncol"},{"issue":"20","key":"1201_CR21","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1002\/sim.1228","volume":"21","author":"D Faraggi","year":"2002","unstructured":"Faraggi D, Reiser B (2002) Estimation of the area under the ROC curve. Stat Med 21(20):3093\u20133106. doi: 10.1002\/sim.1228","journal-title":"Stat Med"},{"issue":"6","key":"1201_CR22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2217\/fon.10.71","volume":"6","author":"E Bustinza-Linares","year":"2010","unstructured":"Bustinza-Linares E, Kurzrock R, Tsimberidou AM (2010) Salirasib in the treatment of pancreatic cancer. Future Oncol 6(6):885\u2013891. doi: 10.2217\/fon.10.71","journal-title":"Future Oncol"},{"issue":"29","key":"1201_CR23","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.2174\/092986706779026219","volume":"13","author":"L Ingrassia","year":"2006","unstructured":"Ingrassia L, Camby I, Lefranc F, Mathieu V, Nshimyumukiza P, Darro F, Kiss R (2006) Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 13(29):3513\u20133527","journal-title":"Curr Med Chem"},{"issue":"4","key":"1201_CR24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/glycob\/cwr173","volume":"22","author":"MC Miller","year":"2012","unstructured":"Miller MC, Klyosov AA, Mayo KH (2012) Structural features for alpha-galactomannan binding to galectin-1. Glycobiology 22(4):543\u2013551. doi: 10.1093\/glycob\/cwr173","journal-title":"Glycobiology"},{"issue":"11","key":"1201_CR25","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2174\/138920112802502051","volume":"13","author":"HM Strik","year":"2012","unstructured":"Strik HM, Kolodziej M, Oertel W, Basecke J (2012) Glycobiology in malignant gliomas: expression and functions of galectins and possible therapeutic options. Curr Pharm Biotechnol 13(11):2299\u20132307","journal-title":"Curr Pharm Biotechnol"},{"issue":"5","key":"1201_CR26","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","volume":"170","author":"H Ohgaki","year":"2007","unstructured":"Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445\u20131453. doi: 10.2353\/ajpath.2007.070011","journal-title":"Am J Pathol"},{"issue":"3","key":"1201_CR27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1179\/016164107X235149","volume":"30","author":"T Krzyszkowski","year":"2008","unstructured":"Krzyszkowski T, Dziedzic T, Czepko R, Szczudlik A (2008) Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res 30(3):294\u2013296. doi: 10.1179\/016164107X235149","journal-title":"Neurol Res"},{"issue":"11","key":"1201_CR28","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3174\/ajnr.A2397","volume":"32","author":"LC Hygino da Cruz Jr","year":"2011","unstructured":"Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978\u20131985. doi: 10.3174\/ajnr.A2397","journal-title":"AJNR Am J Neuroradiol"},{"issue":"4","key":"1201_CR29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1750-3639.2009.00316.x","volume":"19","author":"S Gool Van","year":"2009","unstructured":"Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S (2009) Dendritic cell therapy of high-grade gliomas. Brain Pathol 19(4):694\u2013712. doi: 10.1111\/j.1750-3639.2009.00316.x","journal-title":"Brain Pathol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1201-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-013-1201-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1201-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:17:44Z","timestamp":1559362664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-013-1201-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1007\/s11060-013-1201-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,4]]}}}